The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic liver disease
暂无分享,去创建一个
A E Read | R. Branch | A. Read | R A Branch | J A James | J. A. James
[1] J. J. Curry,et al. THE ESTIMATION OF HEPATIC BLOOD FLOW IN MAN. , 1945, The Journal of clinical investigation.
[2] R. Swartz,et al. Effects of physical stress on the disposition of drugs eliminated by the liver in man. , 1974, The Journal of pharmacology and experimental therapeutics.
[3] R. Branch,et al. Hemodynamic drug interactions: the reduction of oxyphenbutazone clearance by dl-propranol in the dog. , 1973, The Journal of pharmacology and experimental therapeutics.
[4] E. Vesell,et al. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration , 1974, Clinical pharmacology and therapeutics.
[5] W. I. Cranston,et al. Hepatic Uptake and Biliary Excretion of Indocyanine Green in the Dog.∗ , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[6] P. Astrup,et al. Plasma antipyrine half-life and hepatic microsomal antipyrine hydroxylase activity in rabbits. , 1973, Pharmacology.
[7] J. Crooks,et al. Effect of Age and Sex on Human Drug Metabolism , 1971, British medical journal.
[8] B. Brodie,et al. The fate of antipyrine in man. , 1950, The Journal of pharmacology and experimental therapeutics.
[9] M. Rowland,et al. Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. , 1968, Journal of pharmaceutical sciences.
[10] M. Garimoldi,et al. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease , 1972, Gut.
[11] N. Tygstrup,et al. Galactose blood clearance as a measure of hepatic blood flow. , 1958, Clinical science.
[12] S. Sherlock,et al. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. , 1968, Lancet.
[13] G. Mawer,et al. Metabolism of amylobarbitone in patients with chronic liver disease , 1972, British journal of pharmacology.
[14] L. Ranek,et al. Clearance of Antipyrine‐Dependence of Quantitative Liver Function , 1974, European journal of clinical investigation.
[15] R. Branch,et al. A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. , 1976, British journal of clinical pharmacology.
[16] R. Branch,et al. The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction. , 1973, The Journal of pharmacology and experimental therapeutics.
[17] S. Shaldon,et al. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. , 1961, Clinical science.
[18] B. Brodie,et al. The estimation of antipyrine in biological materials. , 1949, The Journal of biological chemistry.
[19] T. Reynolds,et al. Hepatic wedge pressure, blood flow, vascular resistance and oxygen consumption in cirrhosis before and after end-to-side portacaval shunt. , 1958, The Journal of clinical investigation.
[20] P. Turner,et al. Effect of phenobarbitone on hepatic drug-metabolizing enzymes and urinary D-glucaric acid excretion in man. , 1975, British journal of clinical pharmacology.
[21] C. S. Davidson,et al. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. , 1960, The Journal of clinical investigation.
[22] H. Elias,et al. Vascular pattern of the cirrhotic liver. , 1952, American journal of clinical pathology.
[23] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[24] T. Whitsett,et al. The effect of hepatic blood flow on the hepatic removal rate of oxyphenbutazone in the dog. , 1971, The Journal of pharmacology and experimental therapeutics.
[25] C. M. Leevy,et al. Estimation of hepatic blood flow with indocyanine green. , 1962, The Journal of clinical investigation.